Humana (HUM) Q3 2026 Earnings Call: Q&A Summary

Q: Stephen Baxter with Wells Fargo asked about 2027 headwinds and tailwinds, and expectations for individual MA margins.

A: Celeste Mellet noted no incremental headwinds beyond the Stars impact, while tailwinds include OpEx reductions, medical cost improvements, and better product pricing. She expects material margin improvement in 2027.

Q: Justin Lake with Wolfe Research asked about cost trends and pressure in the CenterWell segment.

A: Celeste Mellet stated cost trends are at the lower end of the 7% to 8% range, with 2027 trends expected at 8% to 9% due to the health technology pipeline. She noted that CenterWell pressure in one geography is being addressed through contract changes and improved benefit design.

Q: Matthew Gillmor with KeyBanc asked for the impact of PCO costs and mitigation plans.

A: Celeste Mellet said the impact is not meaningful to the enterprise and expects actions taken by CenterWell and payers to address the pressure.

Q: Ann Hynes with Mizuho asked about 2027 MA membership growth and the competitive environment.

A: Jim Rechtin attributed membership outperformance to improved distribution channel quality, though he noted it is too early to provide specific membership numbers.

Q: David Windley with Jefferies asked about margin targets and the Stars tailwind.

A: Jim Rechtin explained that the tailwind cannot be quantified yet due to competitive dynamics and membership mix, but it will be sufficient to both invest in the business and pass value to shareholders.

Q: Kevin Fischbeck with Bank of America asked about the Stars tailwind and the progression of earnings toward the $40 target.

A: Celeste Mellet confirmed the Stars tailwind is in excess of the target and noted that earnings progression is ahead of plan across all line items.

Q: Andrew Mok with Barclays asked about the mechanics of sharing Stars revenue with capitated partners.

A: Celeste Mellet noted the company insulated value-based care providers from the downside, and any upside above the target is incremental.

Q: Jason Cassorla with Guggenheim Securities asked about capital deployment priorities.

A: Jim Rechtin stated the primary use of capital is funding insurance reserves, followed by organic and inorganic growth in Medicaid and CenterWell. Celeste Mellet added that the company plans to grow the dividend once the payout ratio normalizes and will use buybacks to offset dilution.

Q: Scott Fidel with Goldman Sachs asked about the use of reinsurance in the MA business.

A: Celeste Mellet explained that reinsurance is used for capital efficiency and does not expect a substantial change in its use for 2027.

Q: A.J. Rice with UBS asked about the shift to managing toward top-quartile Stars performance and the strategy for value-based care.

A: Jim Rechtin clarified that managing to top quartile is a discipline to ensure the cost structure is sustainable, though the goal remains to be the best possible. Celeste Mellet added that the company is focusing on aligning with high-quality providers regardless of their risk-taking status.

Q: George Hill with Deutsche Bank asked about the drivers of 2027 margin expansion and the disciplined operating model.

A: Celeste Mellet stated that pricing is the primary driver of improvement, while Jim Rechtin emphasized that the focus is on multi-year planning and operational discipline rather than conservatism.